Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 3/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824874 | 0.91 | POLB (0.49) | CTSAEGLN2EGLN1ALDH1A1LMNA | |
| SCHEMBL5927665 | 0.83 | POLB (0.53) | CTSAALDH1A1LMNAMAPK1 | |
| SCHEMBL5927222 | 0.81 | CTSA (0.44) | CTSAEGLN2EGLN1ALDH1A1LMNA | |
| SCHEMBL4827853 | 0.81 | MME (0.47) | — | |
| SCHEMBL4824681 | 0.81 | MME (0.47) | — | |
| SCHEMBL3992792 | 0.81 | POLB (0.46) | CTSAALDH1A1LMNAMAPK1 | |
| SCHEMBL5926489 | 0.81 | CTSA (0.43) | CTSAEGLN2EGLN1ALDH1A1LMNA | |
| SCHEMBL5927560 | 0.81 | LRRK2 (0.49) | CTSAALDH1A1LMNAMAPK1ACACB | |
| SCHEMBL5926784 | 0.79 | CTSA (0.60) | CTSAALDH1A1LMNAMAPK1MMP12 | |
| SCHEMBL6098336 | 0.79 | MMP12 (0.60) | CTSAMMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | CTSA 1878/4885EGLN2 76/4885EGLN1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.